Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial
Randomized trial demonstrates high effectiveness of pre-exposure prophylaxis against HIV-1 infection, suggesting substantial protection for at-risk populations.
Key Points
To assess the effectiveness of pre-exposure prophylaxis in preventing HIV-1 acquisition during the pilot phase of the PROUD trial.
Conducted a pragmatic, open-label randomized trial assessing pre-exposure prophylaxis (PrEP) against HIV-1 infection.
Coordinated by the MRC Clinical Trials Unit at UCL in partnership with Public Health England and Gilead Sciences.
Daily pre-exposure prophylaxis demonstrated strong effectiveness in reducing the incidence of HIV-1 acquisition in real-world clinic settings.